Major Exscientia deal with Merck21 Sep 2023 08:45
Https://uk.advfn.com/stock-market/london/frontier-ip-FIPP/share-news/Frontier-IP-Group-plc-Exscientia-announces-collabo/92091952
" Portfolio news - Exscientia announces AI drug discovery collaboration with Merck KGaA, Darmstadt, Germany worth up to $674 million
Frontier IP, a specialist in commercialising intellectual property, today notes the following announcement from portfolio company Exscientia plc ("Exscientia" or the "Company") of a new collaboration with Merck KGaA, Darmstadt, Germany, ("Merck") focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology.
Under the terms of the agreement, Exscientia will receive an upfront cash payment of $20 million from Merck and will be eligible for discovery, development, regulatory and sales-based milestone payments of up to $674 million in aggregate if all milestones for three initial programmes are achieved.
Frontier IP holds a 0.4 per cent equity stake in Exscientia.
Exscientia statement begins:
-- Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany
-- Collaboration will leverage Exscientia's precision design capabilities to focus on previously unsolved drug design challenges
-- Exscientia is eligible to receive up to $674 million in discovery, development, regulatory and sales-based milestones for three projects, in addition to single to double digit royalty payments on net sales
-- Up to $113 million of potential milestone payments in the discovery phase, with $20 million upfront at initiation for three projects
OXFORD, U.K. Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilise Exscientia's AI-driven precision drug design and discovery capabilities while leveraging Merck KGaA, Darmstadt, Germany's disease expertise in oncology and neuroinflammation, clinical development capabilities and global footprint.
Three potential first-in-class or best-in-class targets have been identified as the initial focus of the partnership. The collaboration allows Merck KGaA, Darmstadt, Germany and Exscientia to identify additional targets in oncology and immunology or other mutually agreed disease areas. Should Exscientia identify additional targets for the collaboration, the company would be responsible for target validation in addition to drug design and eligible for additional discovery milestones.
etc"